Illumina Inc. has agreed to pay $9.8 million to resolve allegations that it violated the False Claims Act after the company sold genomic sequencing systems with cybersecurity vulnerabilities to federal agencies, according to the U.S. Department of Justice.
Illumina, headquartered in California, manufactured and sold genomic sequencing systems throughout the U.S. The settlement resolves allegations that between 2016 and 2023, Illumina sold government agencies genomic sequencing systems with software that had cybersecurity vulnerabilities, without having an adequate security program and systems to identify and address those vulnerabilities, according to the DOJ.
The government contended that Illumina knowingly failed to: incorporate product cybersecurity in its software design, development, installation, and on-market monitoring; failed to properly support and resource personnel, systems, and processes tasked with product security; failed to correct design features that introduced cybersecurity vulnerabilities in the genomic sequencing systems; and falsely represented that the software on the genomic sequencing systems adhered to cybersecurity standards.
The settlement resolves a lawsuit filed under the whistleblower provisions of the False Claims Act, in which private parties can sue on behalf of the government when a defendant has submitted false claims for government funds and receive a share of any recovery. The settlement in this case provides for the whistleblower,...
Imagine you receive a phone call claiming that your family member got into trouble, and you need to pay a fine to avoid getting into more trouble. This scenario is very common across Europe. Fraud...